Impact of methotrexate on oxidative stress and apoptosis markers in psoriatic patients.
Methotrexate (MTX), a cytotoxic chemotherapeutic agent, is considered an effective drug in the treatment of psoriasis. The aim of this study was to find out whether the effect of MTX treatment in psoriasis is due to oxidative stress-induced apoptosis. Psoriasis vulgaris patients (58 in number) were recruited for this study. Healthy volunteers (45 in number) served as control. Samples of psoriatic patients were collected and analyzed for total reactive oxygen species (ROS), malondialdehyde (MDA) levels, nitrite, nitrate levels and the activities of antioxidants like superoxide dismutase (SOD), catalase (CAT) and total antioxidant status (TAS) and also the protein expression of caspase-3, before (Day 0) and after (at the end of 6 and 12 weeks) MTX treatment. Our results show a significant increase in tissue ROS and plasma MDA after MTX treatment when compared with before MTX treatment in psoriasis patients (p < 0.001). The levels of serum nitrite and nitrate were decreased significantly after MTX treatment (p < 0.001). The activities of plasma SOD, TAS and serum CAT levels were decreased, but not significantly after 12 weeks of treatment. The expression of caspase-3 was increased after MTX treatment. In conclusion, MTX induce apoptosis through oxidative stress by reducing NO and increasing caspase-3 levels. MTX-induced apoptosis may account for the beneficial effect of MTX treatment in psoriasis patients, which is characterized by acanthosis.
Department of Medical Research, SRM Medical College, Hospital and Research Centre, Kattankulathur, 603203, Tamilnadu, India.
Tamilselvi
T
Elango
Haripriya
H
Dayalan
Pushpa
P
Gnanaraj
Hemamalini
H
Malligarjunan
Swapna
S
Subramanian
D000293:Adolescent; D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000032:analysis; D017209:Apoptosis / Q000187:drug effects*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D009566:Nitrates / Q000097:blood; D009573:Nitrites / Q000097:blood; D018384:Oxidative Stress / Q000187:drug effects*; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology*; D017382:Reactive Oxygen Species / Q000032:analysis; D055815:Young Adult
D000975:Antioxidants; D003879:Dermatologic Agents; D009566:Nitrates; D009573:Nitrites; D017382:Reactive Oxygen Species; D008315:Malondialdehyde; D008727:Methotrexate